New Oral Agent for Treatment of Anemia in Patient with Chronic Kidney Disease: Prolyl Hydroxylase Inhibitor
- Author:
KiRyang NA
1
Author Information
- Publication Type:Review
- Keywords: Prolyl hydroxylase inhibitor; Anemia; Hepcidin; ESA
- MeSH: Anemia; Anemia, Refractory; Anoxia; Erythropoiesis; Hematinics; Hepcidins; Humans; Hypertension; Inflammation; Iron; Mortality; Prolyl Hydroxylases; Renal Insufficiency, Chronic
- From:Korean Journal of Medicine 2019;94(1):11-16
- CountryRepublic of Korea
- Language:Korean
- Abstract: Hypoxia inducible factor (HIF)-stabilizers are being developed for the renal anemia treatment. This small molecules inhibit prolyl hydroxylase domain (PHD)-containing enzymes, causing HIF activation instead of degradation under the state of normoxia, finally increase production of intrinsic erythropoiesis. Current treatment guidelines suggest that renal anemia should be treated mainly with iron and erythropoiesis stimulating agents (ESAs). But there are several complications and concerns such as hypertension, ESA refractory anemia and increased cardiovascular mortality in using ESAs. Advantages of HIF stabilizers over ESAs are orally available, no dose-up requirement for inflammation. So far new HIF stabilizers showed efficacy and safety in renal anemia treatment. This new therapeutic agent may emerge as a standard treatment option for renal anmia treatment.
